Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LstCAR019 in Relapsed/Refractory B-ALL
NCT05571540Phase 2Withdrawn
- Sponsor
- Kunming Hope of Health Hospital
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cd19 universal car-t cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Kunming Hope of Health Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of Treatment Related adverse events at 12 months. Planned start Oct 2022; status: withdrawn.
02
Drugs
cd19 universal car-t cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05571540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571540.